Please assess the completion status of the following clinical trial:

Trial Title: Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Donor Eligibility Criteria:~* Age 18-60~* A history of a positive nasopharyngeal swab for COVID-19 or a history of positive antibody titer test.~* At least 14 days from resolution of COVID-19-associated symptoms including fevers.~* A negative nasopharyngeal swab (or similar test) for COVID-19~* anti-SARS-CoV2 titers \>1:500~* Adequate venous access for apheresis~* Meets donor eligibility criteria in accordance to Hackensack University Medical Center (HUMC) Collection Facility at the John Theurer Cancer Center (JTCC) if collecting at the JTCC, and all regulatory agencies as describes in SOP 800 01.~* Required testing of the donor and product must be performed in accordance to FDA regulations (21 CFR 610.40), and the donation must be found suitable (21 CFR 630.30)~Recipient Eligibility Criteria:~* Patient age \>30 years old, newly diagnosed with a COVID-19 infection with onset of first symptoms \< 96 hours.~* And least one other high-risk feature:~  1. Age \> 65~ 2. BMI 30 or above~ 3. Hypertension, defined as SBP above 140 or DBP above 90, or requiring medication for control.~ 4. Coronary artery disease (history, not ECG changes only)~ 5. Congestive heart failure~ 6. Peripheral vascular disease (includes aortic aneurysm \>= 6 cm)~ 7. Cerebrovascular disease (history of CVA or TIA)~ 8. Dementia~ 9. Chronic pulmonary disease~ 10. Liver disease (such as portal hypertension, chronic hepatitis)~ 11. Diabetes (excludes diet-controlled alone)~ 12. Moderate or severe renal disease defined as having a GFR \< 60 mL/min~ 13. Cancer (exclude if \> 5 year in remission)~ 14. AIDS (not just HIV positive)~Recipient exclusion criteria:~* History of severe transfusion reaction to plasma products~* Need for oxygen supplementation~* Positive test for COVID-19 antibodies~* Chemotherapy-induced neutropenia (ANC \< 0.5 x 103/mcL)~* Immunosuppressive medications except for prednisone (or steroid equivalent) \> 10 mg daily.~* Performance status \< 50 by KPS~* Pneumonia by radiographic evaluation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Convalescent Plasma (Type: EXPERIMENTAL): Fresh or frozen plasma will be infused one time to patients
- Best Supportive Care (Type: ACTIVE_COMPARATOR): Patients will receive best supportive care. Patients randomized to best supportive care may receive plasma should they require hospitalization for progression of COVID-19 disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).